Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01358578 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,306
- Enrollment target
NCT01358578 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,306 participants.
The verdict
NCT01358578, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,306 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of secukinumab compared to placebo and etanercept in patients that have moderate to severe, chronic, plaque-type psoriasis.
Interventions
- DRUG Placebo
- DRUG etanercept
- DRUG secukinumab (AIN457)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,306 participants |
| Start Date | 2011-06 |
| Est. Completion | 2013-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01358578
The ClinicalTrials.gov registry entry for NCT01358578 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,306 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01358578 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01358578 about?
NCT01358578 is a clinical study titled "Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis". This study will assess the safety and efficacy of secukinumab compared to placebo and etanercept in patients that have moderate to severe, chronic, plaque-type psoriasis.
What is the current status of trial NCT01358578?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,306 participants. The study started on 2011-06. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01358578?
The interventions under investigation include: Placebo (DRUG), etanercept (DRUG), secukinumab (AIN457) (DRUG).
Who is sponsoring clinical trial NCT01358578?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.